A Phase 2, multicenter, open-label, non-randomized, proof-of-concept study evaluating the efficacy, safety, and tolerability of SAR445088 in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)

Chronic inflammatory demyelinating polyradiculoneuropathy

Part A, SOC-Treated: Percentage of participants relapsing after withdrawal of SOC and during the SAR445088 treatment period, Part A, SOC-Refractory (initial and low dose group) and SOC-Naïve: Percentage of participants responding during the SAR445088 treatment period, Part B: Number of participants reported with adverse events

Part A: Number of participants reported with adverse events, Part A: Number of participants with incidence and titer of anti-SAR445088 antibodies (ADA), Part A: Percentage of participants in the SOC-Treated group improving during the overlap treatment period, Part B, SOC-Treated (initial dose group): Percentage of participants relapse-free during the treatment extension period, Part B, SOC-Refractory (initial and low dose group) and SOC-Naive: Percentage of participants with sustained response during the treatment extension period, Part B: Long-term immunogenicity

No related papers found yet.

France, Germany, Italy, Netherlands, Poland, Spain